• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • Preparation Tips MCQ PG
    • Target PG Books and Bruno Books : Medical Books authored by J Mariano Anto Bruno Mascarenhas
      • Target PG Series TNPSC 2nd Edition (16 Papers from 1995 to 2007)
      • Zulfi Raj’s Pre PG Medicine HandBook 4th Edition – Revised by Bruno
      • TargetPG TNPSC Interview Buster Assistant Surgeon Recruitment
      • FirsTest Series – Orthopaedics
      • Tamil Nadu PG Entrance Review – Bruno – PARAS – TargetPG
    • MCQs
  • Exams Calendar
    • Institution Wise
    • Post Graduate ( PG ) Medical Entrance Exam Schedule / Calendar 2013
    • Post Graduate ( PG ) Medical Entrance Exam Schedule / Calendar 2012
  • About Us
    • Feedback, Contact Us, Discuss, Know Related Sites
  • List of All Categories

TargetPG

Target Professional Growth / Post Graduation - a helping hand to the hands that heal

  • Home
  • AIPG
    • AIPPG 2014
    • AIPPG 2012
    • AIPPG 2011
    • AIPPG 2010
      • All India 2010 Allotment
      • All India 2010 Counselling
    • AIPPG 2009
      • All India 2009 Allotment
      • All India 2009 Counselling
    • AIPPG 2008
    • AIPPG 2007
    • AIPPG 2006
    • AIPPG 2005
    • AIPPG 2004
    • AIPPG 2003
  • AIIMS
    • AIIMS 2014 May
    • AIIMS 2013 Nov
    • AIIMS 2012 Nov
    • AIIMS 2012 May
    • AIIMS 2011 Nov
    • AIIMS 2009 Nov
    • AIIMS 2009 May
    • AIIMS 2008 Nov
    • AIIMS 2008 May
    • AIIMS 2007 Nov
    • AIIMS 2006 Nov
    • AIIMS 2006 May
    • AIIMS 2003 Nov
  • TNPG
    • TNPG 2014
    • TNPG 2013
    • TNPG 2012
    • TNPG 2011
    • TNPG 2010
    • TNPG 2009
    • TNPG 2008
    • TNPG 2007
    • TNPG 2006
    • TNPG 2005
    • TNPG 2004
    • TNPG 2003
    • TNPG 2002
  • TN Tamil Nadu
    • 10 A 1 Appointment
    • 10 A 1 Rules
  • TNPSC
    • Special TNPSC 2013
    • Special TNPSC 2009
    • General TNPSC 2009
    • TNPSC 2008 MHO
    • Special TNPSC 2007
    • TNPSC 2007 MHO
    • General TNPSC 2005
    • General TNPSC 2003
    • Departmental Exams
  • UPSC
    • CMS 2010
    • Armed Forces
  • DipNB DNB
    • FMGE
  • CET NEET
  • MBBS
  • MCI
  • Central Institutes
    • PGI Chandigarh
    • SGPGIMS Lucknow
    • JIPMER
    • NIMHANS
    • NIMS Hyderabad
    • SCTIMST Trivandrum
    • CIP Ranchi
    • IMS BHU Varanasi
    • AFMC Pune
    • INHS Aswini
    • IGNOU
    • JNU Jawaharlal Nehru University New Delhi
  • Private
    • CMC Vellore
    • CMC Ludhiana
    • St.John’s Medical College Bangalore
    • Annamalai University
    • SRMC
    • MANIPAL MAHE
    • COMED-K
    • RGUHS
    • Apollo Medvarsity
    • BR PRIVATE MEDICAL COLLEGE ASSOCIATION, BIHAR
  • Courses
You are here: Home / Topics / Clinical Ethical Legal Issues / Compulsory licensing provision under Indian Patents law : A historic move to make drugs affordable

Compulsory licensing provision under Indian Patents law : A historic move to make drugs affordable

March 14, 2012 by TargetPG Leave a Comment

SLASH AND CURE: Compulsory licensing is perfectly legal and built into the patents regime to balance corporate profit and public interest. Photo: Bijoy Ghosh

Though this topic is not related to Entrance Exams or MCQs, we are giving it here, as we feel that this is a significant step in Indian Health Care Delivery

From http://www.thehindu.com/opinion/op-ed/article2991869.ece

SLASH AND CURE: Compulsory licensing is perfectly legal and built into the patents regime to balance corporate profit and public interest. Photo: Bijoy Ghosh
SLASH AND CURE: Compulsory licensing is perfectly legal and built into the patents regime to balance corporate profit and public interest. Photo: Bijoy Ghosh
The government’s decision to grant a compulsory licence for the manufacture of an important anti-cancer drug should be the first step towards making available essential drugs at little or no direct cost.

India’s use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs.

The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is a landmark event, consistent with the test of public interest that governs such a measure. Under Section 84 of the Indian Patents Act, 1970, any person can make an application to the Controller for a compulsory licence after the expiry of three years from the date of sealing of the patent, on the following grounds — non-fulfilment of reasonable requirements of the public, or non-availability of the invention to the public at a reasonable price. The Trade-Related Aspects of Intellectual Property Rights and the Doha Declaration provide for compulsory licensing in specified circumstances, including concerns on public health or public interest.

Licence till 2021

Mere application of the test of reasonable price in a country with a weak social health insurance infrastructure provides a strong argument for compulsory licensing in the case of Nexavar, the patent for which is held by the German multi-national company, Bayer. At present a month’s treatment regime of 120 tablets costs Rs.2.84 lakh, but manufacture under compulsory licensing will slash it to Rs.8,880. The Indian applicant has been granted the licence till the expiry of the patent in 2021.

The use of compulsory licensing is bound to raise the temperature in the pharmaceutical industry and be dubbed a move that will stifle innovation. But that would be ignoring the point that it is perfectly legal, and is in fact provided for in the patents regime to balance public interest and corporate profits. Use of the provision has been advocated by the High Level Experts Group (HLEG) of the Planning Commission headed by Dr. K. Srinath Reddy, to address the issue of lack of access to essential drugs and affordability.

The question of drug access and prices has become particularly important after India changed over from a regime that recognises process patents for medicines to one of patents for products, since 2005. The effects are expected to be felt most acutely in the case of new drugs, notably those relating to cancer, HIV/AIDS and psychiatric conditions. Further, the Planning Commission HLEG has drawn attention to more possible negative outcomes if enhanced provisions of TRIPS Plus, which would enable “evergreening” of patents beyond 20 years, are applied.

Producing drugs is, no doubt, an expensive business, and significant funds are invested in research and rigorous testing. The drugs developed through this process have great impact on the well-being of people. Yet, patents can also produce monopolies, and thus immense power for corporations. It is important to remember that patents deal with intellectual property, which, unlike other property, produces no conflict over use. Use by one person does not cause any rivalry with another and thus has no marginal costs.

Medical prize fund

The economist and Nobel Laureate, Joseph E. Stiglitz summed up the problem in the British Medical Journal five years ago thus: Restricting the use of medical knowledge not only affects economic efficiency, but also life itself. We tolerate such restrictions in the belief that they might spur innovation, balancing costs against benefits. But the costs of restrictions can outweigh the benefits. He cited in particular, the discovery and patenting of genes linked to breast cancer, a development that would, in countries without a national health service, deprive many poor women access to the expensive test. As a departure from the corporate-led pathways of innovation, which often invest in lifestyle drugs research rather than life-saving formulations, Professor Stiglitz advocated a medical prize fund to spur innovation, with large rewards for discoverers of cures or vaccines for scourges such as malaria, and smaller rewards for others that are similar to existing drugs. Such intellectual property would then be open to generic drug manufacturers.

Issue of pricing

In the absence of effective intervention by the government, drug pricing can produce expensive distortions. Indians consumed about Rs.56,000 crore worth of medicines through private chemists in the open market, going by March 2011 figures submitted to the Planning Commission. What is revealing is that the price gap between government procurement of drugs and retail sale can be staggeringly wide — between 100 per cent and 5,000 per cent. Moreover, the price index for medicines has parted from the index for all commodities and moved steadily upward, since 1997-98. This is clear evidence of unethical pricing of many medicines for rising profit, using patents as a cover, as well as lack of regulation.

The bold move on compulsory licensing should be a first step in a process of reform and price controls that will make available essential drugs to all Indians at little or no direct cost. Drawing up a strong essential drug list to suit the current national disease profile is important. The public sector pharmaceutical industry and its capability to produce generic drugs have a strong role to play in such a plan, and deserves encouragement to revive its fortunes. This initiative is crucial to the universal health coverage that the Indian government wants to provide to all its citizens in coming years, starting with the Twelfth Plan. It should also serve as a clear signal to pharmaceutical companies to stop extracting staggering profits from a market with weak social support mechanisms.

anant@thehindu.co.in

Filed Under: Clinical Ethical Legal Issues Tagged With: Media Coverage Reports

Reader Interactions

Leave a Reply Cancel reply

You must be logged in to post a comment.

Primary Sidebar

If you can’t find what you looked for, just search

Latest and Recent Events / Notifications

  • AYUSH in Madras Medical College
  • NIMHANS Entrance 2017 Crash Course at Chennai
  • CRASH COURSE NEET 2016 / AIIMS / JIPMER November 2016 @ MADURAI, CHENNAI, NELLAI, COIMBATORE
  • MRB 2014 Counselling Delay. The Way Forward
  • Walk-in Selection for Assistant Surgeons Specialty MRB Tamil Nadu 2014 2015

All Posts Sorted Categorywise

All Posts Sorted Monthwise

Tags

2nd Second Round Counseling 2004 2008 2009 2010 2011 2012 2013 2014 Admit Card Hall Ticket Exam Centre Allotment Analysis Opinion Answers Ask TargetPG : Doubts Answered Change in Policies Coaching Conferences Seminars Workshops Focus Groups Counseling DME DPH Editorial Entrance FAQ Government Government Order Government Service Judgements Media Coverage Reports MGR Medical University MRB : Medical Services Recruitment Board Notification OHC - Operation Harri Capsule : Crash Course for AIIMS PGI and AIPG Exams Paramedical Pass Fail Pozitive Positive Prospectus Questions Results Theory Written Marks Merit Rank List Rural Service Selection List Service Quota Strategies SuperSpeciality Uncategorized Vacancy

Footer

Recent Comments

  • luxawish on TN MRB Results 2013 Assistant Surgeon Medical Recruitment Board Tamil Nadu List of 2074 Doctors Selected
  • Berita Pertanian Hari Ini on Health Officers by transfer of service from the post of Assistant Surgeons working in Primary Health Centres
  • Shahid shaikh on About TargetPG : Target Professional Growth / Post Graduation : a helping hand to the hands that heal
  • Dr.Ashwini on TN MRB Results 2013 Assistant Surgeon Medical Recruitment Board Tamil Nadu List of 2074 Doctors Selected
  • bhuvantvmc on TN MRB Results 2013 Assistant Surgeon Medical Recruitment Board Tamil Nadu List of 2074 Doctors Selected

RSS Feeds

Click here to Get Our RSS Feed to read latest events without visiting the site
RSS Subscribers

Follow @TargetPG

Follow @targetpg

Mailing List

Join our Mailing List
Mailing List of TargetPG at Google Groups
Email:
Click to join the Mailing List

Our Facebook Page

Website Design and Maintenance by OSQ Digital

Website Design and Maintenance by OSQ Digital

Copyright © 2002 to 2021 : TargetPG * Target Professional Growth / Post Graduation - a helping hand to the hands that heal * Notifications, Results, Old Question Papers, Answers with references, High Yield Points & Strategies with respect to the Indian Medical Post Graduate PG Entrance Exams like AIIMS,AIPG, JIPMER, CMC Vellore, PGI Chandigarh, UPSC, TNPSC, State PG Exams like Tamil Nadu PG (TN PG), Delhi PG, UPPG, Tamilnadu PG (TNPG), Karnataka PG etc * This is a FREE Portal and is intended for the benefit of PG Aspirants * consult@doctorbruno.net * Call / Whatsapp 9940626911 * Powered by WordPress · Log in